"Excited about getting some more alignment and taking some unknowns out of the equation" as it pertains to the path market-ward, CEO Nick Leschly said Bluebird Bio Inc. will consider bringing on a partner to help with Lentiglobin BB305 for beta-thalassemia major "if it makes sense for capabilities, ideally not for finances."